Vanda Pharmaceuticals (NASDAQ:VNDA) posted its quarterly earnings results on Thursday. The company reported ($0.79) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.29) by $0.50, Stock Ratings Network.com reports. The company had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.50 million. During the same quarter last year, the company posted ($0.15) earnings per share. Vanda Pharmaceuticals’ revenue was up 12.3% compared to the same quarter last year. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) net profit margin is -59.90% and weekly performance is -30.97. On last trading day company shares ended up $10.14. Analysts mean target price for the company is $24.33. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) distance from 50-day simple moving average (SMA50) is -33.99%.
On May 1, 2014, Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued a press release announcing its financial results for the first quarter of 2014. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares fell -12.33% in last trading session and ended the day on $11.09. CLDX its return on assets is -34.40%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) quarterly performance is -52.46%.
XOMA Corporation (NASDAQ:XOMA), a leader in the discovery and development of therapeutic antibodies, on 7 may announced its operational highlights and financial results for the first quarter ended March 31, 2014. XOMA Corp (NASDAQ:XOMA) shares moved down -18.53% in last trading session and was closed at $3.43, while trading in range of $3.42 – $4.14. XOMA Corp (NASDAQ:XOMA) year to date (YTD) performance is -49.03%.
Galena Biopharma Inc. (NASDAQ:GALE) continues to enjoy commercial progress at the back of Abstral advancing cancer immunotherapies. 2014 is expected to be a turnaround year for the company with Abstral sales expected to reach a guidance of between $11 million and $15 million. Going forward Galena is already planning for three major milestones in terms of initiating Phase 3 PRESENT trial, as well as Phase 2 trial with GALE-401. Galena Biopharma Inc. (NASDAQ:GALE) ended the last trading day at $2.33. Company weekly volatility is calculated as 10.61% and price to cash ratio as 5.75. Galena Biopharma Inc. (NASDAQ:GALE) showed a negative weekly performance of -4.51%.